The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of ...

US FDA approves Bristol-Myers Squibb’s antipsychotic drug, Cobenfy for treatment of schizophrenia: Maryland Saturday, September 28, 2024, 09:00 Hrs [IST] The US Food and Drug Ad ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

With Thursday approval from the U.S. Food and Drug Administration for Cobenfy, adults living with schizophrenia will have ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...

This trial is looking at different ways to improve treatment for Ewing’s sarcoma. It’s mainly looking at changes to chemotherapy and radiotherapy.

BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis ...